Vernalis Plc (VER)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013491
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vernalis plc (Vernalis) is a pharmaceutical company, which focuses at developing novel pharmaceuticals for the treatment of several diseases. The product portfolio of the company comprises frovatriptan for the acute treatment of migraine; Tuzistra XR, which targets the US prescription cough cold market; and Moxatag, a once-a-day formulation of the antibiotic (amoxicillin), indicated for the treatment of tonsillitis and pharyngitis secondary to Streptococcus pyogenes. It also specializes in fragment and structure based drug discovery. The company has collaboration agreements with pharmaceutical companies, including Novartis, Endo, GSK, Genentech, Biogen Idec, AKP, Menarini, Lundbeck, Servier, Taisho and Tris. It has operations in Europe and North America. Vernalis is headquartered in Winnersh, the UK.

Vernalis Plc (VER) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vernalis Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Vernalis Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Vernalis Plc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Vernalis Acquires US rights to MOXATAG from Pragma Pharma 11
Partnerships 12
Vernalis and Servier Enter into Discovery Agreement 12
Vernalis Enters into Research Agreement with Taisho Pharma 13
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 14
Vernalis And Servier Extend Oncology Drug Discovery Agreement 15
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 16
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 17
Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier 18
Licensing Agreements 19
Corvus Pharma Amends its Licensing Agreement with Vernalis 19
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 20
Vernalis Enters Into Licensing Agreement With Tris Pharma For Cough And Cold Products 21
Vernalis Enters into Licensing Agreement with RedoxTherapies 23
Equity Offering 24
Vernalis to Raise USD58 Million in Private Placement of Shares 24
Vernalis Completes Private Placement Of Ordinary Shares For US$31 Million 25
Vernalis Completes Public Offering Of Ordinary Shares For US$77.7 Million 26
Vernalis Plc – Key Competitors 27
Vernalis Plc – Key Employees 28
Vernalis Plc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 31
Financial Announcements 31
Sep 12, 2017: Vernalis: Results Announcement for the year ended 30 June 2017 31
Jul 18, 2017: Vernalis: Year-End Trading Update and Notice of Full Year Results 33
Feb 21, 2017: Vernalis: Unaudited Interim Results for the six months ended 31 December 2016 34
Sep 29, 2016: Vernalis Announces Results Announcement for the 12 Months Ended 30 June 2016 36
Mar 17, 2016: Vernalis: Unaudited Interim Results Announcement for the six months ended 31 December 2015 38
Mar 17, 2016: Vernalis Announces Unaudited Interim Results Announcement for the Six Months Ended 31 December 2015 43
Corporate Communications 44
Apr 21, 2016: Vernalis Appoints Sandford Sommer as President & Chief Operating Officer, Vernalis Therapeutics 44
Government and Public Interest 45
Dec 01, 2016: Vernalis: AGM Statement 45
Product News 46
12/21/2016: FDA accepts CCP-08 NDA for full review 46
09/06/2016: Vernalis annopunces that FDA accepts CCP-07 NDA for full review 47
04/05/2017: Drug makes head-and-neck cancer more sensitive to radiotherapy 48
Product Approvals 49
Aug 07, 2017: FDA Issues a Complete Response Letter on CCP-08 NDA 49
Apr 21, 2017: FDA Issues a Complete Response Letter on CCP-07 NDA 50
Clinical Trials 51
Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study 51
Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study 52
Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Vernalis Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vernalis Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vernalis Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Vernalis Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Vernalis Acquires US rights to MOXATAG from Pragma Pharma 11
Vernalis and Servier Enter into Discovery Agreement 12
Vernalis Enters into Research Agreement with Taisho Pharma 13
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 14
Vernalis And Servier Extend Oncology Drug Discovery Agreement 15
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 16
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 17
Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier 18
Corvus Pharma Amends its Licensing Agreement with Vernalis 19
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 20
Vernalis Enters Into Licensing Agreement With Tris Pharma For Cough And Cold Products 21
Vernalis Enters into Licensing Agreement with RedoxTherapies 23
Vernalis to Raise USD58 Million in Private Placement of Shares 24
Vernalis Completes Private Placement Of Ordinary Shares For US$31 Million 25
Vernalis Completes Public Offering Of Ordinary Shares For US$77.7 Million 26
Vernalis Plc, Key Competitors 27
Vernalis Plc, Key Employees 28
Vernalis Plc, Subsidiaries 29

★海外企業調査レポート[Vernalis Plc (VER)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Honeywell Advanced Fibers and Composites:企業の戦略・SWOT・財務情報
    Honeywell Advanced Fibers and Composites - Strategy, SWOT and Corporate Finance Report Summary Honeywell Advanced Fibers and Composites - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Intrexon Corp (XON)-製薬・医療分野:企業M&A・提携分析
    Summary Intrexon Corp (Intrexon), formerly Genomatix Corp is a provider of therapeutic solutions. The company operates through its divisions such as human therapeutics, protein production, industrial products, agricultural biotech, and animal sciences. Its human therapeutics division develops therap …
  • ethris GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Ethris GmbH (Ethris) is a biotech company that develops RNA-based therapies. The company develops therapeutics based on its proprietary platform technologies. It uses technologies including magnetovax and SNIM RNA. Ethris’ magnetovax is a platform for personalized tumor vaccines localized an …
  • Hyundai Motor Co (005380)-エネルギー分野:企業M&A・提携分析
    Summary Hyundai Motor Company (Hyundai) is a global manufacturer of automobiles, which designs, develops and manufactures passenger and heavy duty automobiles and relevant parts. The company manufactures passenger cars under various brand names such as Centennial, Genesis, Veloster, Azera, Sonata, i …
  • Cumberland Pharmaceuticals Inc (CPIX):製薬・医療:M&Aディール及び事業提携情報
    Summary Cumberland Pharmaceuticals Inc (Cumberland Pharma) is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products. Its primary target markets are hospital acute care, gastroenterology and cancer supportive care. The company offers branded presc …
  • Baltimore Gas and Electric Co:企業の発電所・SWOT分析2018
    Baltimore Gas and Electric Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • WPPI Energy Inc:企業の戦略的SWOT分析
    WPPI Energy Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Arconic Inc (ARNC):企業の財務・戦略的SWOT分析
    Arconic Inc (ARNC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Simons Group Ltd:企業の戦略・SWOT・財務分析
    Simons Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Simons Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Profire Energy Inc (PFIE):企業の財務・戦略的SWOT分析
    Summary Profire Energy Inc (Profire Energy) is an oilfield technology company that undertakes design, development, and installation of combustion management technology and chemical injection solutions. The company offers products such as burner management systems and chemical management systems. Its …
  • Five Star Senior Living Inc (FVE):製薬・医療:M&Aディール及び事業提携情報
    Summary Five Star Senior Living Inc (Five Star), formerly Five Star Quality Care Inc is a healthcare service provider that offers senior living and patient care services. The center’s services include independent living, assisted living, skilled nursing care, memory care, dining and nutrition, hospi …
  • TaiDoc Technology Corporation (4736):企業の財務・戦略的SWOT分析
    TaiDoc Technology Corporation (4736) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • G4S Plc (GFS):企業の財務・戦略的SWOT分析
    G4S Plc (GFS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Illumina, Inc.:企業の戦略・SWOT・財務情報
    Illumina, Inc. - Strategy, SWOT and Corporate Finance Report Summary Illumina, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Sasol Ltd (SOL):石油・ガス:M&Aディール及び事業提携情報
    Summary Sasol Ltd (Sasol) is an integrated energy and chemicals company. It develops and commercializes technologies; and builds and operates facilities to produce a range of products, including liquid fuels, chemicals, and low-carbon electricity. The company’s product offerings include olefins and …
  • Kyushu Electric Power Company, Incorporated:企業の戦略・SWOT・財務分析
    Kyushu Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Kyushu Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Mitsui Chemicals, Inc.:企業の戦略・SWOT・財務分析
    Mitsui Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mitsui Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • JetBlue Airways Corp:企業の戦略・SWOT・財務分析
    JetBlue Airways Corp - Strategy, SWOT and Corporate Finance Report Summary JetBlue Airways Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Tokyo Electric Power Company Holdings Incorporated (9501):電力:M&Aディール及び事業提携情報
    Summary Tokyo Electric Power Company Holdings Incorporated (TEPCO) is an energy utility. It generates, transmits and distributes electricity; transports fuel; and retails electricity and gas. The company produces power using coal, gas, LNG, solar, wind and hydro sources. TEPCO has presence in the en …
  • Cantabio Pharmaceuticals Inc (CTBO):製薬・医療:M&Aディール及び事業提携情報
    Summary Cantabio Pharmaceuticals Inc (Cantabio Pharmaceuticals) is a biotechnology company that concentrates on the commercializing of novel therapies for Parkinson’s disease, Alzheimer’s disease and neurodegenerative diseases. The company provide pipeline product candidates such as CB101 and CB102, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆